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Summary Intensity-modulated radiation therapy (IMRT) is an evolution of 3D conformal radi-
ation therapy, which is the current standard radiation therapy technique in head-and-neck
cancer. Modulating the radiation intensity of each beam by dynamic interposition of the
computer-assisted collimator leaves yields dose distributions that are particularly well adapted
to head-and-neck tumor volumes. It is thus possible to predetermine dose per element: i.e., the
minimum effective dose to be delivered to tumor areas, and the maximum to be safely delivered
to organs at risk. The technique thereby enables complex tumoral targets to be optimally cov-
ered, while sparing healthy tissue, and salivary glands in particular. In addition, the technique
allows dose-escalation, with a higher dose per session delivered to the macroscopic tumor
than to other irradiated areas. The ﬁrst results of ongoing randomized trials conﬁrmed those
of earlier comparative studies, showing marked improvement in side effects, including post-
radiation xerostomia. Although the positive impact of this technique on tumor control remains
to be proven, salivary function conservation currently makes IMRT the standard treatment in
most head-and-neck cancer.
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IntroductionIntensity-modulated radiation therapy (IMRT) represents a
major evolution in the treatment of head-and-neck can-
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er, enhancing the therapeutic ratio by increasing the dose
elivered to the tumoral volume while reducing that to
ealthy organs.
In head-and-neck cancer, it is particularly difﬁcult to
nsure a good therapeutic ratio:tumors are often large and/or poorly radiosensitive,
requiring high therapeutic doses, equal to or greater
than 70Gy delivered in 35 fractions over 7 weeks for
served.
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macroscopic lesions and equal to or greater than 50Gy
delivered in 25 fractions over 5 weeks for microscopic
lesions;
lesion conﬁguration is often ballistically complex, signiﬁ-
cantly different from simple geometric forms;
many healthy at-risk organs are present within the target
areas.
Most technical improvements in X-ray treatment tech-
iques aim to reduce the impact of these issues, either by
mproved tumor contouring or by adapting dose distribu-
ion to tumor volume, shape and extension. Considerable
dvances in computer-assisted medicine have greatly
mproved the quality and precision of medical imaging.
adiation therapy (RT) has been quick to apply these
mprovements in target visualization. 3D representation of
umoral targets and healthy at-risk organs has become ever
ore effective, enabling more adapted dose distribution.
hese kinds of improved technique go under the general
ame of ‘‘conformal 3D RT’’, which is currently the most
idespread standard. More recently, further advances have
een developed, including IMRT, which is in fact simply a
ophisticated evolution of conformal 3D RT.
rom conformal 3D RT to intensity-modulated
adiation therapy
he evolution in RT techniques over the last 30 years began
rom 2D radiation therapy using coplanar beams, usually in
pposing pairs: e.g., right and left lateral in head-and-neck
ncology. Dose distribution was calculated without taking
ccount of tissue heterogeneity, simply according to the skin
ontour of the target volume. Interposing lead caches here
nd there in the ﬁeld helped protect sensitive areas, in what
as an early attempt at ‘‘conformal’’ RT.
3D RT was developed using CT data, to determine both
he anatomic contours of tissues and organs and radiologic
ensity differentials directly applicable in dosimetrics. As
T data were obtained in all slice planes, 3D reconstruction
as possible both for tumor volume and extension and neigh-
oring healthy tissue, and for the dose distribution achieved
y the selected treatment protocol. Interposing protection
ithin the beam and, later, using the multi-leaf collimators
vailable in modern linear accelerators made 3D conformal
T the standard technique by the turn of the century.
IMRT is an evolution of the above technique, involving a
hange in strategy: hitherto, therapeutic radiation needed
o be as homogeneous as possible, to ensure that the
ntire target volume received the prescribed dose, with
either ‘‘underdoses’’, incurring a risk of recurrence,
or ‘‘overdoses’’, incurring a risk of post-intervention
omplications.
In reality, however, optimal therapeutic radiation should
ake account of differing treatment objectives within a
iven target area: maximal dose delivered to tumoral vol-
mes and minimal dose to neighboring healthy tissue. Such
adiation will be highly heterogeneous in pattern, entailing
paradigm shift away from the previous aim of radiation
omogeneity.
IMRT enables modulation of both the number of ﬁelds
nd the radiation intensity within each ﬁeld. This allows an
i
n
o
cigure 1 Schema of the intensity-modulated radiation ther-
py technique.
nﬁnite range of dose distributions, adaptable to (almost)
ny target volume conﬁguration. In fact, this evolution
as only possible because the ‘‘internal’’ (CT) contours
ad become accessible, collimators had become multi-leaf,
ith leaf movement able to modulate beam intensity dur-
ng the actual delivery, and the algorithms and calculation
ethods allowed all of the above data to be integrated.
hus, during a given session, certain collimator leaves are
nterposed within the beam for variable time intervals,
hereby ‘‘modulating’’ radiation intensity (Fig. 1).
This possibility of ‘‘sculpting’’ dose distribution, so as to
mprove the match between radiation and tumor volumes
nd to exclude critical healthy organs from the maximal
adiation area, obviously led to inverting the classical treat-
ent planning procedure.
This conceptual inversion brought about by the possibility
f modulating beam intensity is indeed known as ‘‘inverse
lanning’’, and consists of the following successive steps:
contouring volumes of interest (target tumor volumes and
healthy organs to be spared) on CT slices acquired with
the patient in treatment position, often enriched with
combined MRI and PET data;
predetermination of dose parameters: minimum and/or
maximum levels to be delivered to target tumor volumes
and at-risk healthy organs, respectively;
data entry on dedicated dosimetric planning software
which calculates the optimal ballistic arrangement, the
contribution of each ﬁeld and the resultant radiation
intensity modulation according to the above geometric
and dosimetric criteria (Fig. 2).
The procedure could be roughly summed up as ‘‘Set your
ose levels and locations, and let the computer get on with
t’’! While things are a little more complicated than that,
evertheless the resultant ballistic pattern and contribution
f each beam do optimize dose distribution as compared to
lassical 3D conformal RT.
IMRT for head and neck cancers 243
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oFigure 2 Stages of implementation
Technique
IMRT uses linear accelerators equipped with multi-leaf
collimators with leaf movement controlled by dedi-
cated software. Schematically, two technical solutions are
available:
1) a succession of usually ﬁve to seven ﬁxed accelerator
positions around a circle or arc; so-called ‘‘step and
shoot’’ radiation is thus delivered at each position, with
intensity modulated by interposition of the collimator
leaves;
2) radiation delivered during rotation through an arc, with
continuous intensity modulation, known as ‘‘dynamic
IMRT’’ (VMat, Elekta; Rapid’Arc, Varian), which signiﬁ-
cantly reduces exposure time.
One dedicated system enables circular intensity-
modulated radiation associated to simultaneous translation
of the treatment table, and thus of the patient, resulting
in a helical pattern of radiation; this technique, known as
tomotherapy (TomoTherapy, Hi·Art System), also includes a
built-in scanner for continuous target tracking.
Finally, there is a new device, a real ‘‘Swiss army knife’’
for RT (Novalis TX, Varian), enabling single (radiosurgery) or
fractionated (stereotactic RT) dose stereotactic radiation.
The relevant targets are small volume and either exclusively
cerebral (Gamma Knife, Elekta) or cerebral and extracere-
bral (Cyberknife, Accuray). Except for the Gamma knife,
these devices can also deliver intensity-modulated radia-
tion. A recent publication reviews the various technical
means currently available for IMRT [1].
m
a
atensity-modulated radiation therapy.
ationale for intensity-modulated radiation
herapy in head-and-neck cancer
MRT provides three combinable advantages in treatment:
relative conservation of healthy tissue;
improved tumor coverage;
and escalation of the dose delivered to the tumor.
Head-and-neck cancers can clearly beneﬁt from these
hree factors, given their generally high level of sever-
ty, copresence of numerous healthy organs and frequently
omplex ballistic conﬁgurations. There is thus a need to opti-
ize control of locally advanced (stages II and III) tumors,
n a dose-escalation strategy; the numerous healthy at-
isk organs within the target volume entail a risk of severe
omplication or functional sequelae; the irregular conﬁ-
uration of the target tumor volumes entails a risk of
oncave lesions around major healthy organs (retropharyn-
eal adenopathy, posterior lymph-node extension, etc.).
The ﬁrst treatment applications of IMRT date back to the
ate 1990s, so that reliable assessment of efﬁcacy is now
ossible, although there are still no comparative studies
n head-and-neck indications objectively demonstrating the
dvantages of the technique. It does, nevertheless, seem
easonable that a technique providing sharp dose gradi-
nts within the target volume will be well adapted to the
peciﬁc anatomic conﬁgurations involved in head-and-neck
ncology, which tend to be narrow, with no more than a
illimetric separation between tumor and at-risk organs.
At the same time, the side effects and complications
ssociated with head-and-neck RT are especially serious
nd disabling; acute per-treatment effects are almost sys-
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Figure 3 Example of dose distribution during intensity-
modulated radiation therapy in an axial slice through the
o
d
t
m
t
i
n
b
e
d
I
T
E
W
a
t
p
w
b
c
m
a
o
a
m
d
i
P
I
e
t
r
b
r
v
t
‘
c
i
o
(
t
s
c
m
t
l
a
w
e
p
L
i
T
i
•
•
•
•
v
a
c
o
c
i
e
R
e
t
s
I
i
Iropharynx (T1N0 left tonsil squamous-cell carcinoma after
iagnostic tonsillectomy).
ematic, but transitory, while late-onset effects at several
onths’ or years’ distance tend to be deﬁnitive, with lit-
le hope for improvement. The list of possible late effects
s especially long, ranging from rare but extremely serious
eurological damage to mere skin epilation. Xerostomia is
y far the most frequent side effect, signiﬁcantly impairing
locution, swallowing, taste and quality of life and inducing
entomandibular septic complications.
ndications in head-and-neck oncology
he indications follow from the advantages inherent to IMRT.
xclusive radiation (tumor in situ)
here the prime objective is to spare healthy tissue such
s salivary parenchyma, IMRT is especially well-suited to
reating carcinoma of the oropharynx or nasopharynx. If the
rime objective is to spare neural tissue, the technique is
ell-suited to radiation treatment of the facial sinuses, skull
ase or nasopharynx.
The prime treatment objective may also be to optimize
overage of a complex tumor volume as in radiation treat-
ent of nasosinal cavity, nasopharynx or retropharyngeal
nd/or spinal lymph-node area carcinoma.
Finally, treatment may involve dose-escalation, as in non-
perated locally advanced grade II or III tumor; IMRT then
llows delivery of a concurrent boost: a higher dose in the
acroscopic tumor volume than in other areas irradiated
uring the session. Suprahyoid tumor is generally a good
ndication for IMRT, often for all three above reasons (Fig. 3).ostoperative radiation
ndications in postoperative radiation are currently under
valuation. Contouring volumes of interest, and especially
t
s
b
eN. Daly-Schveitzer et al.
umor volume, is inherently difﬁcult as the tumor has been
esected. Moreover, remaining anatomic structures have
een altered by surgical closure, in terms of position and
elation. It is, for example, very difﬁcult to contour ‘‘tumor
olume’’ reliably after transmandibular buccopharyngec-
omy, subtotal glossectomy or radical curage. In such cases,
‘classical’’ 3D conformal RT may be a safer option, espe-
ially as the dose to be delivered tends to be lower than
n exclusive radiation. Even so, IMRT still has the obvi-
us advantage of ensuring relative conservation of healthy
especially salivary) tissue, which can greatly enhance func-
ional comfort after associated RT and surgery.
There are, however, cases where evaluation is more
traightforward: postoperative radiation of facial sinus
ancer, for example, is an excellent indication for IMRT inas-
uch as the remaining bone structures allow the various
reatment volumes to be contoured from ﬁxed anatomic
andmarks. Certain complex reconstruction ﬂaps may also
llow postoperative contouring of the initial tumor volume
hich they have replaced. In all cases, discussion and coop-
ration between surgeon and radiotherapist is essential for
ostoperative IMRT treatment planning.
imitations and requirements of
ntensity-modulated radiation therapy
he dose gradients induced by IMRT within the target volume
nvolve certain obvious risks related to:
the impossibility of determining tumor extension with mil-
limetric precision, especially when infraclinical;
the difﬁculty of achieving perfect patient immobility,
even with the latest contention systems, during a session
which usually lasts 15—20minutes;
visceral movements related to breathing and swallowing;
and reduction in tumor volume and/or in patient
morphology, particularly due to weight loss during the
period of treatment.
It is therefore necessary to set a margin around the
olume of interest to limit the impact of abrupt dose vari-
tion. With regard to movement, several techniques are
urrently being developed to introduce a ‘‘4D’’ generation
f conformal RT whereby movement of the target will be
ontinuously followed throughout the session, although this
s not indispensable in head-and-neck oncology, notably for
xample in suprahyoid tumor. Finally, so-called ‘‘adaptive’’
T reconstructs the real dose delivered to the target after
ach session, taking account of change in morphology during
reatment so as to enable corrections to be made in the
ubsequent session.
mproved tumor control by
ntensity-modulated radiation therapy
nsofar as dose distribution under IMRT is systematically bet-
er adapted than in classical RT, particularly as concerns
uprahyoid tumor and especially when near to the skull
ase, it is reasonable to suppose that tumor control will be
nhanced—and results published so far bear this out.
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Figure 4 Dose distribution in an axial slice during IMRT for
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Most studies, however, have not been randomized but
simple retrospective comparative designs. At the same time,
target volume deﬁnition techniques (CT, MRI and PET) have
greatly progressed, which may in itself account for the
improvements reported [2]. This said, it nevertheless seems
highly likely that IMRT provides better results than classical
conformal RT in skull base, facial sinus and nasopharyngeal
tumor.
Initial results have been conﬁrmed in more recent series,
such as that of Daly [3], with 107 oropharyngeal cancer
patients treated by concurrent IMRT and chemotherapy and
a 92% rate of local control at 3 years and a 6% rate of late
complication of grade IV or more. The European GORTEC
group is currently running a randomized study, which is at
present at the inclusion stage, to compare the two types of
technique (GORTEC trial 2004-01).
The advantages of IMRT are perhaps less clear in infrahy-
oid locations; relatively few series, however, have as yet
been published regarding these indications. Target volumes
are easier to contour in these anatomic areas, so that the
argument from improved deﬁnition by improved imaging
loses some of its force. On the other hand, the risk of upper
lymph-node extension, notably in hypopharyngeal tumor,
requires placing the superior limit of radiation at the base of
the skull, which underlines the inherent dosimetric advan-
tages of IMRT [4]. At all events, data on infrahyoid tumor
remain few and limited, and hyperfractionation designs
remain a valid option, as do associations of concurrent radi-
ation and chemotherapy.
Altered fractionation and intensity-modulated
radiation therapy
Daily hyperfractionation and/or treatment acceleration
have been clearly shown to improve local control of
head-and-neck carcinoma, while reducing the rate of
late complication. The radiation therapy oncology group
(RTOG)’s phase III trial reported 8% improvement with
respect to standard daily monofractionated treatment [5].
The introduction of IMRT, and of associated radiation-
chemotherapy, has led to a signiﬁcant drop in indications for
hyperfractionation, as the logistical demands of implement-
ing several sessions per day are too heavy for most centers
[6—8]. An elegant way of combining the two attitudes is
the simultaneous integrated boost technique (SIB) [9]. With
IMRT, in a given session, different doses can be delivered to
different parts of the target: greater than 2Gy to the tumor
volumes or areas at elevated risk of invasion, while keeping
the dose delivered to areas at risk of microscopic tumor at
or below 2Gy. To date, however, there is still no objective
proof of beneﬁt as compared either to classic RT or to IMRT
without SIB.
Associated intensity-modulated radiation
therapy-chemotherapyAssociated radiation-chemotherapy, especially when
concurrent, improves local control and may limit metastatic
spread—although the latter point is controversial [10—13].
This is achieved, however, at the cost of increased general
c
m
phinopharyngeal carcinoma, showing doses delivered to the
ain salivary glands.
nd local toxicity. The question then is whether IMRT aggra-
ates such local reactions to the point of compromising the
easibility of associated radiation-chemotherapy. A study by
he New York MSKCC reported no signiﬁcant difference with
espect to classical RT associated to chemotherapy [14].
ssociation to so-called targeted therapy would not seem
o incur any particular problems beyond increased acute
ucositis, especially in case of cetuximab administered
imultaneously to SIB [15,16].
alivary and at-risk organ sparing by
ntensity-modulated radiation therapy
t the present time, only retrospective comparisons are
vailable, but these all point to a considerable reduction
n the incidence of severe xerostomia. Thus, the 2002 UCSF
eries [17] of 67 nasopharyngeal cancer patients at a median
1 months’ follow-up showed a 64% rate of grade II xerosto-
ia at 3 months, falling to only 2.4% by 2 years, with 66% of
atients free of any xerostomia [18,19].
It is now agreed that salivary parenchyma sparing with
he resultant reduction in xerostomia risk is one ben-
ﬁt associated with IMRT, clearly improving endobuccal
rophicity and reducing infection risk and late dental lesions
9,19—22]. Nutting et al. [23] recently published the ﬁrst
andomized study, conﬁrming parotid-sparing under IMRT
ompared to classical conformal RT.
A mean dose of 26Gy delivered to the salivary glands
ppears to be maximal if substantial salivary conservation is
ought (Fig. 4). It should, however, be borne in mind that the
egree of conservation of salivary ﬂow does not correlate
irectly with patients’ self-reported comfort: objectively
onsiderable conserved salivary ﬂow may be associated with
uch less positive subjective experience.
Claus et al. reported IMRT in 47 facial sinus cancer
atients; acute and subacute palpebro-ocular side effects
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ere greatly reduced, but follow-up was too short to assess
eurologic side effects [24,25]. Finally, the study by Eisbruch
t al. [26] suggested that the relative sparing of pharyngeal
onstrictor muscles achieved by IMRT may improve long-
erm swallowing comfort.
rawbacks of intensity-modulated radiation
herapy
MRT delivers highly heterogeneous radiation to the treated
olume, with very narrow transitions between high and
oderate or low dose areas. This means that any inexac-
itude in geometry may endanger a healthy at-risk organ
r, worse, allow local recurrence. Contouring lesion vol-
mes, preferential extensions and neighboring at-risk organs
n the CT slices is thus a critical step, requiring regular
ractice in integrating all of the data provided by clini-
al, endoscopic and peroperative examination, multimodal
maging and possibly pathology reports. In the recent liter-
ture, however, local recurrence following IMRT principally
ccurred within the target volume and especially within the
ross tumor volume, and much more rarely in marginal loca-
ions [22,27,28].
In contrast, when treating very evolved tumor, and par-
icularly in case of large cervical adenopathies inducing
bnormal drainage channels, there is a risk of recurrence
reas that are intentionally under-dosed in an effort to spare
t-risk organs such as the parotids [29].
The preliminary medical step of contouring can take 1 to
hours, and is followed by an essentially physical step con-
ucted by radiophysicists and dosimetrists, which is equally
ong as rigorous quality assurance has to be implemented.
inally, during treatment as such, position controls are more
requent than in classical RT: ﬁrst daily and then several
imes per week, as changes in geometry during treatment
weight loss, edema, tumor shrinkage, etc.) have to be taken
nto account due to the steep dose gradients inherent to this
echnique.
Given the range of human and technical resources imple-
ented in IMRT, costs are signiﬁcantly higher than in
lassical RT, although the current pricing approach in the
rench health system does not really take this into account
30].
Finally, IMRT may increase the risk of radiation-induced
ancer. RT is known to entail a slight but real increase
n the risk of subsequent cancer, which has been assessed
ith precision in patients treated for cancer in childhood
nd adolescence. IMRT considerably increases the volume
f tissue receiving low dose radiation, so that increased risk
f radiation-induced cancer is quite plausible although not
roven. This may contraindicate IMRT in children, but should
ot stand in its way for the treatment of head-and-neck
ancer in adults.
onclusion
n all, IMRT clearly appears to represent a major progress
n the management of head-and-neck cancer. Widespread
se is as yet hindered by the qualitative and quantita-
ive demands in terms of human and technical resources
equired for optimal implementation. Its ability, however, to
[N. Daly-Schveitzer et al.
mprove both local control and subsequent quality of life will
robably make it a standard, although it should be stressed
hat the publication of the results of the rare comparative
rials currently underway will be needed before the beneﬁts
f the technique can be deﬁnitively conﬁrmed or not.
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